02 FC:1814

130.00 DA

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) ALLE6002-100 [17400CIP(OCU)]
In re Application of: James A. Burke et al.	
Application No.: 09/998,718	
Filed: 11/01/2001	
For: Methods and Compositions for Treatment of Ocular Neovascularization and Naural Injury	
The owner*, Allergan Inc., of 100 percent interest in the instant application hereby disclaims, e part of the statutory term of any patent granted on the instant application which would extend statutory term prior patent No. 8,194,415 as the term of said prior patent is defined in 35 U.s. said prior patent is presently shortened by any terminal disclaimer. The owner hereby agreinstant application shall be enforceable only for and during such period that it and the prior agreement runs with any patent granted on the instant application and is binding upon the granted on the instant application and is binding upon the granted.	beyond the expiration date of the full S.C. 154 and 173, and as the term of es that any patent so granted on the patent are commonly owned. This
In making the above disclaimer, the owner does not disclaim the terminal part of the term application that would extend to the expiration date of the full statutory term as defined in patent, "as the term of said prior patent is presently shortened by any terminal disclaimer, later:	35 U.S.C. 154 and 173 of the prior
expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination cartificate; is refssued; or is in any manner terminated prior to the expiration of its full statutory term as presently shor	tened by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnershipetc.), the undersigned is empowered to act on behalf of the business/organization.	p, university, government agency,
I hereby declare that all statements made herein of my own knowledge are true; information and belief are believed to be true; and further that these statements were made w statements and the like so made are punishable by fine or imprisonment, or both, under Sec States Code and that such willful false statements may jeopardize the validity of the application	rith the knowledge that willful false tion 1001 of Title 18 of the United
2. The undersigned is an attorney of record. Reg. No. 33,433	m 7/19/06
Signature	Date
Stephen Donovan	
Typed or printe	ed name
714-246-2	046
Tele	ephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information and authorities the control of the	ormation should not zation on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandría, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandría, VA22313-1450.

"Statement under 37 CFR 3.73(b) is required if terminal discialmer is signed by the assignee (owner).

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form PTO/SB/98 may be used for making this certification. See MPEP § 324.